PLX-PAD

Cell therapy

—no market stage

Evidence outlook

Studies registered, no market-specific stage

Studies of this drug are registered, but none is matched to a market this site covers, so no stage is set and there is nothing to grade. The registry list shows each study.

Featured evidence outside this drug's tracked markets:NCT03451916 · Hip Fracture · Phase 3 · missed primary endpoint · ungraded

Development in Atherosclerotic Cardiovascular Disease stopped for reasons the sponsor has not stated. Source

Development in Critical Limb Ischemia stopped (2020-12) after a negative readout. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT03451916 · Pluristem Ltd.
2018-07-26 – 2023-09-06 · Hip Fracture
What this study did
Phase 2 (3)
Other / comorbidity
NCT04389450 · Pluristem Ltd.
2020-10-01 – 2023-06-07 · COVID, ARDS
What this study did
NCT04614025 · Pluristem Ltd.
2020-10-19 – 2023-02-07 · COVID, ARDS
What this study did
NCT01679990 · Pluristem Ltd.
2012-11-05 – 2019-02-09 · Intermittent Claudication, Peripheral Artery Disease
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01525667 · Pluristem Ltd.
2012-11 – 2015-06 · Total Hip Arthroplasty, Muscle Injury
What this study did
Phase 1 (3)
Other / comorbidity
NCT01795950 · United Therapeutics
2013-04 – 2016-01 · Pulmonary Arterial Hypertension
What this study did
NCT00919958 · Pluristem Ltd.
2009-06 – 2012-06 · Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
What this study did
NCT00951210 · Pluristem Ltd.
2009-08 – 2011-10 · Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
What this study did

Competitive landscape

This drug's own stage for Osteoarthritis: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
PLX-PAD: this drugStage not on recordCell therapyMesenchymal stem cells (immunomodulatory, pro-angiogenic)not yet gradedNo reviewed efficacy summary in this indication
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
EloralintidePhase 3PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
AllocetraPhase 2Cell therapyMacrophage reprogrammingnot yet gradedNo reviewed efficacy summary in this indication
VutiglabridinPhase 2Small moleculeparaoxonase-2 (PON2)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.